|
1
|
Glickman MH and Ciechanover A: The
ubiquitin-proteasome proteolytic pathway: destruction for the sake
of construction. Physiol Rev. 82:373–428. 2002.PubMed/NCBI
|
|
2
|
Ferrell K, Wilkinson CR, Dubiel W and
Gordon C: Regulatory subunit interactions of the 26S proteasome, a
complex problem. Trends Biochem Sci. 25:83–88. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frezza M, Schmit S and Dou QP: Targeting
the ubiquitin-proteasome pathway: an emerging concept in cancer
therapy. Curr Top Med Chem. 11:2888–2905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yerlikaya A and Yöntem M: The significance
of ubiquitin proteasome pathway in cancer development. Recent Pat
Anticancer Drug Discov. 8:298–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pandit B and Gartel AL: Thiazole
antibiotic thiostrepton synergize with bortezomib to induce
apoptosis in cancer cells. PLoS One. 6:e171102011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Piperdi B, Ling YH, Liebes L, Muggia F and
Perez-Soler R: Bortezomib: understanding the mechanism of action.
Mol Cancer Ther. 10:2029–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dick LR and Fleming PE: Building on
bortezomib: second-generation proteasome inhibitors as anti-cancer
therapy. Drug Discov Today. 15:243–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shapovalov Y, Benavidez D, Zuch D and
Eliseev RA: Proteasome inhibition with bortezomib suppresses growth
and induces apoptosis in osteosarcoma. Int J Cancer. 127:67–76.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandit B, Bhat UG and Gartel AL:
Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol
Ther. 11:43–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhat UG, Zipfel PA, Tyler DS and Gartel
AL: Novel anticancer compounds induce apoptosis in melanoma cells.
Cell Cycle. 7:1851–1855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tone Y, Tanahashi N, Tanaka K, Fujimuro M,
Yokosawa H and Toh-e A: Nob1p, a new essential protein, associates
with the 26S proteasome of growing Saccharomyces cerevisiae
cells. Gene. 243:37–45. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tone Y and Toh-E A: Nob1p is required for
biogenesis of the 26S proteasome and degraded upon its maturation
in Saccharomyces cerevisiae. Genes Dev. 16:3142–3157. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oehler VG, Yeung KY, Choi YE, Bumgarner
RE, Raftery AE and Radich JP: The derivation of diagnostic markers
of chronic myeloid leukemia progression from microarray data.
Blood. 114:3292–3298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Z, Guo Q, Shi A, Xie F and Lu Q:
Downregulation of NIN/RPN12 binding protein inhibit the growth of
human hepatocellular carcinoma cells. Mol Biol Rep. 39:501–507.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin Y, Peng S, Yu H, Teng H and Cui M:
RNAi-mediated downregulation of Nob1 suppresses the growth and
colony-formation ability of human ovarian cancer cells. Med Oncol.
29:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakoda T, Kasahara N, Hamamori Y and Kedes
L: A high-titer lentiviral production system mediates efficient
transduction of differentiated cells including beating cardiac
myocytes. J Mol Cell Cardiol. 31:2037–2047. 1999. View Article : Google Scholar
|
|
17
|
Soneoka Y, Cannon PM, Ramsdale EE, et al:
A transient three-plasmid expression system for the production of
high titer retroviral vectors. Nucleic Acids Res. 23:628–633. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adams BK, Ferstl EM, Davis MC, et al:
Synthesis and biological evaluation of novel curcumin analogs as
anti-cancer and anti-angiogenesis agents. Bioorg Med Chem.
12:3871–3883. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee SJ, Choi SY, Kim WJ, et al: Combined
aberrant expression of E-cadherin and S100A4, but not β-catenin is
associated with disease-free survival and overall survival in
colorectal cancer patients. Diagn Pathol. 8:992013.
|
|
21
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Derksen PW, Liu X, Saridin F, et al:
Somatic inactivation of E-cadherin and p53 in mice leads to
metastatic lobular mammary carcinoma through induction of anoikis
resistance and angiogenesis. Cancer Cell. 10:437–449. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Debald M, Kaiser C, Abramian A, et al:
Evaluation of E-cadherin, Ki-67 and lymphatic vessel invasion in
abdominal metastases of human breast cancer. Anticancer Res.
33:1971–1975. 2013.PubMed/NCBI
|
|
25
|
Cai Y, Mohseny AB, Karperien M, Hogendoorn
PC, Zhou G and Cleton-Jansen AM: Inactive Wnt/beta-catenin pathway
in conventional high-grade osteosarcoma. J Pathol. 220:24–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
